Citations

Clear

959 citation(s) found for "Service, F J".

Comparison of first-line radiosurgery for small-cell and non-small cell lung cancer brain metastases (CROSS-FIRE)
Rusthoven, Chad G. , Staley, Alyse , Yomo, Shoji , Bernhardt, Denise , Wandrey, Narine , Shafie, Rami A. El , Kraemer, Anna, Padilla, Oscar , Chiang, Veronica , Faramand, Andrew , Wegner, Rodney E. , Hattangadi‐Gluth, Jona A. , Lévy, Antonin , Bernstein, Kenneth , Mathieu, David , Cagney, Daniel , Grills, Inga S., Lee, Cheng-chia, Sheehan, Jason , Kluwe, Christien, Patel, Samir H. , Halasz, Lia M. , Andratschke, Nicolaus , Deibert, Christopher P., Cifarelli, Christopher P. , Debus, Jürgen, Aoyagi, Kyoko , Brown, Paul D. , Alami, Vida, Niranjan, Ajay , Lunsford, L. Dade , Camidge, D Ross, Kavanagh, Brian D. , Serizawa, Toru , Yamamoto, Masaaki, Bernhardt, Denise , Zacharia, Brad E , Andratschke, Nicolaus , Trifiletti, Daniel M , Mathieu, David , Robin, Tyler P. , Gao, Dexiang , Palmer, Joshua D. , Zacharia, Brad E. , Chan, Michael David , Braunstein, Steve , Verma, Vivek, Trifiletti, Daniel M. , Combs, Stephanie Elisabeth , Sato, Yasunori , Higuchi, Yoshinori , Kondziolka, Douglas

Mayo Clinic

JNCI: Journal of the National Cancer Institute | May 4, 2023 | Volume: 115 | Issue: 8 | Pages: 926-936

10.1093/jnci/djad073 | PMID 37142267 Get It

Abstract Introduction Historical reservations regarding stereotactic radiosurgery (SRS) for small-cell lung cancer (SCLC) brain metastases include concerns for short-interval and diffuse central nervous system (CNS) progression, poor prognoses, and increased neurological mortality specific to SCLC histology. We compared SRS outcomes for SCLC and non-small cell lung cancer (NSCLC) where SRS is well established. Methods Multicenter first-line SRS outcomes for SCLC and NSCLC from 2000 to 2022 were retrospectively collected (n = 892 SCLC, n = 4785 NSCLC). Data from the prospective Japanese Leksell Gamma Knife Society (JLGK0901) clinical trial of first-line SRS were analyzed as a comparison cohort (n = 98 SCLC, n = 814 NSCLC). Overall survival (OS) and CNS progression were analyzed using Cox proportional hazard and Fine-Gray models, respectively, with multivariable adjustment for cofactors including age, sex, performance status, year, extracranial disease status, and brain metastasis number and volume. Mutation-stratified analyses were performed in propensity score–matched retrospective cohorts of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) positive NSCLC, mutation-negative NSCLC, and SCLC. Results OS was superior for patients with NSCLC compared to SCLC in the retrospective dataset (median OS = 10.5 vs 8.6 months; P < .001) and in the JLGK0901 dataset. Hazard estimates for first CNS progression favoring NSCLC were similar in both datasets but reached statistical significance in the retrospective dataset only (multivariable hazard ratio = 0.82, 95% confidence interval = 0.73 to 0.92, P = .001). In the propensity score–matched cohorts, there were continued OS advantages for NSCLC patients (median OS = 23.7 [EGFR and ALK positive NSCLC] vs 13.6 [mutation-negative NSCLC] vs 10.4 months [SCLC], pairwise P values < 0.001), but no statistically significant differences in CNS progression were observed in the matched cohorts. Neurological mortality and number of lesions at CNS progression were similar for NSCLC and SCLC patients. Leptomeningeal progression was increased in patients with NSCLC compared to SCLC in the retrospective dataset only (multivariable hazard ratio = 1.61, 95% confidence interval = 1.14 to 2.26, P = .007). Conclusions After SRS, SCLC histology was associated with shorter OS compared to NSCLC. CNS progression occurred earlier in SCLC patients overall but was similar in patients matched on baseline factors. SCLC was not associated with increased neurological mortality, number of lesions at CNS progression, or leptomeningeal progression compared to NSCLC. These findings may better inform clinical expectations and individualized decision making regarding SRS for SCLC patients.
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
Harrison, Claire , Nangalia, Jyoti , Boucher, Rebecca H. , Jackson, Aimee , Yap, Christina , O’Sullivan, Jennifer , Fox, Sonia, Ailts, Isaak , Dueck, Amylou C. , Geyer, Holly L. , Nadezhdin, Eugene, Curto‐García, Natalia , Green, Anna , Wilkins, Bridget S., Coppell, Jason, Laurie, John , Garg, Mamta , Ewing, Joanne, Knapper, Steven , Crowe, Josephine , Koutsavlis, Ioannis , Godfrey, Anna L. , Arami, Siamak , Drummond, Mark W., Clark, Fiona , Mead‐Harvey, Carolyn , Baxter, E. Joanna , Mead, Adam J. , Dueck, A. C. , Harrison, Claire N , Boucher, Rebecca , Mesa, Ruben , Dunn, William G , Garg, Mamta , Knapper, Steven , Crowe, Josephine , Koutsavlis, Ioannis , Arami, Siamak , Byrne, Jennifer , Baxter, Elizabeth Joanna , McMullin, Mary Frances , Mead, Adam J , Yap, Christina , Mesa, Ruben A. , Dunn, William G. , Chen, Frederick , Byrne, Jenny , McMullin, Mary Frances

Mayo Clinic

Journal of Clinical Oncology | May 1, 2023 | Volume: 41 | Issue: 19 | Pages: 3534-3544

10.1200/jco.22.01935 | PMID 37126762 Get It

PURPOSE Polycythemia vera (PV) is characterized by JAK/STAT activation, thrombotic/hemorrhagic events, systemic symptoms, and disease transformation. In high-risk PV, ruxolitinib controls blood counts and improves symptoms. PATIENTS AND METHODS MAJIC-PV is a randomized phase II trial of ruxolitinib versus best available therapy (BAT) in patients resistant/intolerant to hydroxycarbamide (HC-INT/RES). Primary outcome was complete response (CR) within 1 year. Secondary outcomes included duration of response, event-free survival (EFS), symptom, and molecular response. RESULTS One hundred eighty patients were randomly assigned. CR was achieved in 40 (43%) patients on ruxolitinib versus 23 (26%) on BAT (odds ratio, 2.12; 90% CI, 1.25 to 3.60; P = .02). Duration of CR was superior for ruxolitinib (hazard ratio [HR], 0.38; 95% CI, 0.24 to 0.61; P < .001). Symptom responses were better with ruxolitinib and durable. EFS (major thrombosis, hemorrhage, transformation, and death) was superior for patients attaining CR within 1 year (HR, 0.41; 95% CI, 0.21 to 0.78; P = .01); and those on ruxolitinib (HR, 0.58; 95% CI, 0.35 to 0.94; P = .03). Serial analysis of JAK2V617F variant allele fraction revealed molecular response was more frequent with ruxolitinib and was associated with improved outcomes (progression-free survival [PFS] P = .001, EFS P = .001, overall survival P = .01) and clearance of JAK2V617F stem/progenitor cells. ASXL1 mutations predicted for adverse EFS (HR, 3.02; 95% CI, 1.47 to 6.17; P = .003). The safety profile of ruxolitinib was as previously reported. CONCLUSION The MAJIC-PV study demonstrates ruxolitinib treatment benefits HC-INT/RES PV patients with superior CR, and EFS as well as molecular response; importantly also demonstrating for the first time, to our knowledge, that molecular response is linked to EFS, PFS, and OS.
Surgical service and distance traveled drive patient preference for Care Hotel: a retrospective cohort study
Maniaci, Michael J. , Fazio, Jacey R., Maita, Karla C. , Love, Ellen A., Boyle, Venessa L., Paulson, Margaret R. , Maita, Karla , Paulson, Margaret R , Forte, Antonio Jorge , Maniaci, Michael J , Chadha, Ryan , Love, Ellen A, Heckman, Michael G. , Johnson, Patrick W. , Forte, Antonio J.

Mayo Clinic

Annals of Medicine & Surgery | April 21, 2023 | Volume: 85 | Issue: 5 | Pages: 1578-1583

10.1097/ms9.0000000000000704 | PMID 37229076 Get It

Background: Mayo Clinic’s Care Hotel is a virtual hybrid care model which allows postoperative patients to recover in a comfortable environment after a low-risk procedure. Hospitals need to understand the key patient factors that promote acceptance of the Care Hotel if they are to benefit from this innovative care model. This study aims to identify factors that can predict whether a patient will stay at Care Hotel. Materials and methods: This retrospective chart review of 1065 patients was conducted between 23 July 2020, and 31 December 2021. Variables examined included patient age, sex, race, ethnicity, Charlson comorbidity index, distance patient travelled to hospital, length of surgery, day of the week of surgery, and surgical service. Associations of patient and surgery characteristics with the primary outcome of staying at the Care Hotel were assessed using unadjusted and multivariable logistic regression models. Results: Of the 1065 patients who met criteria for admission to the Care Hotel during the study period, 717 (67.3%) chose to stay at the Care Hotel while 328 (32.7%) choose to be admitted to the hospital. In multivariable analysis, there was a significant association between surgical service and staying at the Care Hotel (P<0.001). Specifically, there was a higher likelihood of staying at the Care Hotel for patients from Neurosurgery [odds rato (OR)=1.86, P=0.004], Otorhinolaryngology (OR=2.70, P<0.001), and General Surgery (OR=2.75, P=0.002). Additionally, there was a higher likelihood of staying at the Care Hotel with distance travelled over 110 miles [OR (per each doubling)=1.10, P=0.007]. Conclusion: When developing a post-surgical care model for patients following outpatient procedures, the referring surgical service is a primary factor to consider in order to ensure patient acceptance, along with patient distance. This study can assist other healthcare organizations considering this model, as it provides guidance on which factors are most indicative of acceptance.
Escaping the Long Shadow Cast by Agranulocytosis
León, José de , Arrojo, Manuel , Verdoux, Hélène , Ruan, Can‐Jun , Schoretsanitis, Georgios , Rohde, Christopher , Cohen, Dan , Schulte, Peter F.J. , Kim, Se Hyun , Cotes, Robert O. , Leung, Jonathan G. , Otsuka, Yuji , Кирилочев, О.О. , Every‐Palmer, Susanna , Clark, Scott R. , Motuca, Mariano , Wilkowska, Alina , Yağcıoğlu, A. Elif Anıl , Lazáry, Judit , Sanz, Emílio J. , Cuevas, Carlos De las , de Leon, Jose , Arrojo-Romero, Manuel , Kirilochev, Oleg O , Baptista, Trino , Grover, Sandeep , Every-Palmer, Susanna , Clark, Scott , McGrane, Ian , Motuca, Mariano , Olmos, Ismael , Wilkowska, Alina , Sagud, Marina , Ignjatovic Ristic, Dragana , Lazary, Judit , Sanz, Emilio J , Leung, Jonathan G , Ruan, Can-Jun , Kim, Se Hyun , Rohde, Christopher , De Las Cuevas, Carlos , Schulte, Peter F J , Anıl Yağcıoğlu, A Elif , Cotes, Robert O , Otsuka, Yuji , Schoretsanitis, Georgios , McGrane, Ian R. , Ristić, Dragana Ignjatović

Mayo Clinic

Journal of Clinical Psychopharmacology | April 17, 2023 | Volume: 43 | Issue: 3 | Pages: 239-245

10.1097/jcp.0000000000001678 | PMID 37068034 Get It

Abstract Purpose/Background A recent article in this journal presented a US perspective regarding the modernization of clozapine prescription and proposed an escape from the long shadow cast by agranulocytosis. Methods Here, an international group of collaborators discusses a point of view complementary to the US view by focusing on worldwide outcomes of clozapine usage that may be uneven in terms of frequency of clozapine adverse drug reactions. Findings/Results Studies from the Scandinavian national registries (Finland and Denmark) did not find increased mortality in clozapine patients or any clear evidence of the alleged toxicity of clozapine. Data on clozapine-associated fatal outcomes were obtained from 2 recently published pharmacovigilance studies and from the UK pharmacovigilance database. A pharmacovigilance study focused on physician reports to assess worldwide lethality of drugs from 2010 to 2019 found 968 clozapine-associated fatal outcomes in the United Kingdom. Moreover, the United Kingdom accounted for 55% (968 of 1761) of worldwide and 90% (968 of 1073) of European fatal clozapine-associated outcomes. In a pharmacovigilance study from the UK database (from 2008 to 2017), clozapine was associated with 383 fatal outcomes/year including all reports from physicians and nonphysicians. From 2018 to 2021, UK clozapine-associated fatal outcomes increased to 440/year. Implications/Conclusions The interpretation of fatal outcomes in each country using pharmacovigilance databases is limited and only allows gross comparisons; even with those limitations, the UK data seem concerning. Pneumonia and myocarditis may be more important than agranulocytosis in explaining the uneven distribution of fatal outcomes in clozapine patients across countries.
Effect of Messaging Content on Engagement With a Short Messaging Service for Perioperative Smoking Cessation
Jose, Thulasee , Cha, Sarah , Graham, Amanda L. , Schroeder, Darrell R. , Warner, David O. , Warner, David O , Jose, Thulasee , Schroeder, Darrell , Graham, Amanda L , Amato, Michael S.

Mayo Clinic

Nicotine and Tobacco Research | April 14, 2023 | Volume: 25 | Issue: 8 | Pages: 1465-1473

10.1093/ntr/ntad061 | PMID 37058426 Get It

Abstract Introduction We determined whether a tobacco cessation intervention targeting brief perioperative abstinence (“quit for a bit”) increased engagement of surgical patients with treatment compared with an intervention targeting long-term postoperative abstinence (“quit for good”). Aims and Methods Surgical patients who smoke were stratified according to intended duration of postoperative abstinence, and then randomized within strata to receive either a “quit for a bit” or a “quit for good” intervention. Both employed initial brief counseling and short message service (SMS) to deliver treatment up to 30 days after surgery. The primary outcome of treatment engagement was defined as the rate at which subjects actively responded to system requests delivered via SMS. Results The engagement index did not differ between intervention groups (median [25th, 75th] of 23.7% [8.8, 46.0] for “quit for a bit” group (n = 48) and 22.2% [4.8, 46.0] for “quit for good” group (n = 50), p = .74), nor did the proportion of patients continuing SMS use after study completion (33% and 28%, respectively). Exploratory abstinence outcomes on the morning of surgery and 7 and 30 days after surgery did not differ between groups. Program satisfaction was high in both groups and did not differ. There was no significant interaction between intended abstinence duration and any outcome, ie, alignment of intent with intervention did not affect engagement. Conclusions Tobacco cessation treatment delivered via SMS was well accepted by surgical patients. Tailoring an SMS intervention to focus on the benefits of short-term abstinence for surgical patients did not increase engagement in treatment or perioperative abstinence rates. Implications Treatment of surgical patients for tobacco use is efficacious and reduces postoperative complications. However, implementation in clinical practice has proved challenging, and new methods of engaging these patients in cessation treatment are needed. We found that tobacco use treatment delivered via SMS was feasible and well utilized by surgical patients. Tailoring an SMS intervention to focus on the benefits of short-term abstinence for surgical patients did not increase engagement in treatment or perioperative abstinence rates. Clinical Trial Number NCT03839043. Registry URL: https://clinicaltrials.gov/ct2/show/NCT03839043
Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes
Magro, Fernando , Pai, Rish K. , Kobayashi, Taku , Jairath, Vipul , Rieder, Florian , Redondo, Isabel, Lissoos, Trevor, Shan, Mingyang, Park, Meekyong, Jairath, Vipul , Jairath, Vipul , Jairath, V , Jairath, V , Magro, F , Jairath, Vipul , Kobayashi, Taku , Redondo, Isabel , Morris, Nathan , Shan, Mingyang , Peyrin‐Biroulet, Laurent

Mayo Clinic

Journal of Crohn's and Colitis | April 14, 2023 | Volume: 17 | Issue: 9 | Pages: 1457-1470

10.1093/ecco-jcc/jjad050 | PMID 37057827 Get It

Abstract Background and Aims To evaluate the effect of mirikizumab, a p19-targeted anti-interleukin-23, on histological and/or endoscopic outcomes in moderately-to-severely active ulcerative colitis [UC]. Methods Endoscopic remission [ER], histological improvement [HI], histological remission [HR], histological-endoscopic mucosal improvement [HEMI], and histological-endoscopic mucosal remission [HEMR] were assessed at Week [W]12 [LUCENT-1: N = 1162, induction] and W40 [LUCENT-2: N = 544, maintenance] for patients randomised to mirikizumab or placebo. Analyses were performed to evaluate predictors of: HEMI at W12 with mirikizumab and HEMR at W40 in patients re-randomised to subcutaneous [SC] mirikizumab; associations between W12 histological/endoscopic endpoints and W40 outcomes in mirikizumab responders re-randomised to mirikizumab SC; and associations between W40 endoscopic normalisation [EN] with/without HR. Results Significantly more patients treated with mirikizumab achieved HI, HR, ER, HEMI, and HEMR vs placebo [p &lt;0.001], irrespective of prior biologic/tofacitinib failure [p &lt;0.05]. Lower clinical baseline disease activity, female sex, no baseline immunomodulator use, and no prior biologic/tofacitinib failure were predictors of HEMI at W12 [p &lt;0.05]. Corticosteroid use and longer disease duration were negative predictors of achieving HEMR at W40 [p &lt;0.05]. W12 HI, HR, or ER was associated with W40 HEMI or HEMR [p &lt;0.05]; ER at W12 was associated with clinical remission [CR] [p &lt;0.05] and corticosteroid-free remission [CSFR] at W40 [p = 0.052]. HR and HEMR at W12 were associated with CSFR, CR, and symptomatic remission at W40. Alternate HEMR [EN + HR] at W40 was associated with bowel urgency remission at W40 [p &lt;0.05]. Conclusions Early resolution of endoscopic and histological inflammation with mirikizumab is associated with better UC outcomes. Clinicaltrials.gov: LUCENT-1, NCT03518086; LUCENT-2, NCT03524092.
Association of Preoperative Growth Differentiation Factor-15 Concentrations and Postoperative Cardiovascular Events after Major Noncardiac Surgery
Duceppe, Emmanuelle , Conen, David , Tiboni, Maria , Kavsak, Peter A. , Srinathan, Sadeesh, Pearse, Rupert M. , Jaffe, Allan S. , Heels‐Ansdell, Diane , Garg, Amit X. , Pettit, Shirley , Sapsford, Robert J., Borges, Flávia K. , Chan, Matthew T.V. , Patel, Ameen , Sessler, Daniel I. , Ofori, Sandra , Jaffe, Allan S. , Devereaux, P.J. , Kavsak, Peter

Mayo Clinic

Anesthesiology | April 11, 2023 | Volume: 138 | Issue: 5 | Pages: 508-522

10.1097/aln.0000000000004539 | PMID 37039711 Get It

Background The association between growth differentiation factor-15 concentrations and cardiovascular disease has been well described. The study hypothesis was that growth differentiation factor-15 may help cardiac risk stratification in noncardiac surgical patients, in addition to clinical evaluation. Methods The objective of the study was to determine whether preoperative serum growth differentiation factor-15 is associated with the composite primary outcome of myocardial injury after noncardiac surgery and vascular death at 30 days and can improve cardiac risk prediction in noncardiac surgery. This is a prospective cohort study of patients 45 yr or older having major noncardiac surgery. The association between preoperative growth differentiation factor-15 and the primary outcome was determined after adjusting for the Revised Cardiac Risk Index. Preoperative N-terminal-pro hormone brain natriuretic peptide was also added to compare predictive performance with growth differentiation factor-15. Results Between October 27, 2008, and October 30, 2013, a total of 5,238 patients were included who had preoperative growth differentiation factor-15 measured (median, 1,325; interquartile range, 880 to 2,132 pg/ml). The risk of myocardial injury after noncardiac surgery and vascular death was 99 of 1,705 (5.8%) for growth differentiation factor-15 less than 1,000 pg/ml, 161 of 1,332 (12.1%) for growth differentiation factor-15 1,000 to less than 1,500 pg/ml, 302 of 1476 (20.5%) for growth differentiation factor-15 1,500 to less than 3,000 pg/ml, and 247 of 725 (34.1%) for growth differentiation factor-15 concentrations 3,000 pg/ml or greater. Compared to patients who had growth differentiation factor-15 concentrations less than 1,000 pg/ml, the corresponding adjusted hazard ratio for each growth differentiation factor-15 category was 1.93 (95% CI, 1.50 to 2.48), 3.04 (95% CI, 2.41 to 3.84), and 4.8 (95% CI, 3.76 to 6.14), respectively. The addition of growth differentiation factor-15 improved cardiac risk classification by 30.1% (301 per 1,000 patients) compared to Revised Cardiac Risk Index alone. It also provided additional risk classification beyond the combination of preoperative N-terminal-pro hormone brain natriuretic peptide and Revised Cardiac Risk Index (16.1%; 161 per 1,000 patients). Conclusions Growth differentiation factor-15 is strongly associated with 30-day risk of major cardiovascular events and significantly improved cardiac risk prediction in patients undergoing noncardiac surgery. Editor’s Perspective What We Already Know about This Topic What This Article Tells Us That Is New
Mechanism of KMT5B haploinsufficiency in neurodevelopment in humans and mice
Sheppard, Sarah E. , Bryant, Laura , Wickramasekara, Rochelle N. , Vaccaro, Courtney, Robertson, Brynn, Hallgren, Jodi , Hulen, Jason, Watson, Cynthia J., Faùndes, Víctor , Duffourd, Yannis , Simon, M. Celeste , Cruz, Xavier de la , Padilla, Natàlia , Flores‐Méndez, Marco , Akizu, Naiara, Smiler, Jacqueline , Silva, Renata Pellegrino da, March, Michael , Diaz‐Rosado, Abdias , Barcelos, Isabella Peixoto de , Choa, Zhao Xiang, Dubourg, Christèle , Journel, Hubert, Démurger, Florence , Mulhern, Maureen , Akman, Cigdem I. , Lippa, Natalie , Baldridge, Dustin , Haeringen, Arie van , Snoeck-Streef, Irina, Chow, Penny , Hing, Anne , Graham, John M. , Faivre, Laurence , Shen, Wei , Mao, Rong , Palumbos, Janice C. , Viskochil, David , Gahl, William A. , Hauser, Natalie , Miller, Rebecca L. , Maffeo, Jessica, Afenjar, Alexandra , Doummar, Diane , Keren, Boris , Macklin‐Mantia, Sarah K. , Meerschaut, Ilse , Zweier, Christiane , Brewer, Carole, Saggar, Anand, Smeland, Marie Falkenberg , Kumar, Ajith , Elmslie, Frances , Deshpande, Charu, Nizon, Mathilde , Ierland, Yvette van , Wilke, Martina , Slegtenhorst, Marjon van, Koudijs, Suzanne M., Chen, Jin Yun, Dredge, David, Pier, Danielle B. , Wortmann, Saskia B. , Kamsteeg, Erik‐Jan , Koch, Johannes , Haynes, Devon , Pollack, Lynda, Titheradge, Hannah , Ranguin, Kara , Denommé‐Pichon, Anne‐Sophie , Weber, Sacha , Fuente, Rubén Pérez de la , Pozo, Jaime Sánchez del, Rosales, José Miguel Lezana , Joset, Pascal , Steindl, Katharina , Mei, Davide , Lespinasse, James, Philippe, Christophe , Dauriat, Benjamin, Raymond, Laure , Cueto‐González, Anna M. , Mignot, Cyril , Grotto, Sarah, Renaldo, Florence , Drivas, Theodore G. , Hennessy, Laura , Parenti, Ilaria , Kaiser, Frank J., Kuechler, Alma, Busk, Øyvind L. , Islam, Lily, Siedlik, Jacob A. , Henderson, Lindsay B. , Juusola, Jane, Person, Richard, Schnur, Rhonda E. , Vitobello, Antonio , Banka, Siddharth , Bhoj, Elizabeth , Stessman, Holly A.F. , Lee, Pearl , Simon, M Celeste , de la Cruz, Xavier , Padilla, Natália , Flores-Mendez, Marco , Akizu, Naiara , Smiler, Jacqueline , Li, Dong , March, Michael , Peixoto de Barcelos, Isabella , Choa, Zhao Xiang , Lim, Chin Yan , Dubourg, Christèle , Mulhern, Maureen , Lippa, Natalie , Andrews, Marisa , Baldridge, Dustin , Constantino, John , Chow, Penny , Faivre, Laurence , Shen, Wei , Palumbos, Janice , Gahl, William , Tifft, Cynthia , Macnamara, Ellen , Keren, Boris , Macklin, Sarah , Meerschaut, Ilse , Callewaert, Bert , Reis, André , Smeland, Marie F , Kumar, Ajith , Elmslie, Frances , Deshpande, Charu , van Ierland, Yvette , Wilke, Martina , Koudijs, Suzanne , Pier, Danielle , Wortmann, Saskia , Kamsteeg, Erik-Jan , Haynes, Devon , Titheradge, Hannah , Ranguin, Kara , Denommé-Pichon, Anne-Sophie , Weber, Sacha , Pérez de la Fuente, Rubén , Lezana Rosales, Jose Miguel , Steindl, Katharina , Rauch, Anita , Mei, Davide , Mari, Francesco , Guerrini, Renzo , Tran Mau-Them, Frederic , Moutton, Sébastien , Cueto-González, Anna M , Drivas, Theodore G , Parenti, Ilaria , Busk, Øyvind L , Siedlik, Jacob A , Vitobello, Antonio , Banka, Siddharth , Bhoj, Elizabeth J , Stessman, Holly A F , Sheppard, Sarah E; https://orcid.org/0000-0003-3480-8123, Bryant, Laura; https://orcid.org/0000-0001-8483-8940, Wickramasekara, Rochelle N; https://orcid.org/0000-0003-3090-9357, Lee, Pearl; https://orcid.org/0000-0002-1274-2891, Simon, M Celeste; https://orcid.org/0000-0001-9106-447X, Padilla, Natália; https://orcid.org/0000-0002-7872-2279, Akizu, Naiara; https://orcid.org/0000-0001-9222-6960, Li, Dong; https://orcid.org/0000-0002-2265-6727, March, Michael; https://orcid.org/0000-0001-9173-6862, Barcelos, Isabella Peixoto; https://orcid.org/0000-0002-3843-4520 de, Choa, Zhao Xiang; https://orcid.org/0000-0002-1838-7931, Lim, Chin Yan; https://orcid.org/0000-0002-1585-002X, Mulhern, Maureen; https://orcid.org/0000-0001-8642-4741, Joset, Pascal; https://orcid.org/0000-0002-4349-9951, Steindl, Katharina; https://orcid.org/0000-0002-4425-3072, Rauch, Anita , al, et

Mayo Clinic

Science Advances | April 10, 2023 | Volume: 9 | Issue: 10 | Pages: No page available

10.1126/sciadv.ade1463 | PMID 36897941 Get It

Pathogenic variants in KMT5B , a lysine methyltransferase, are associated with global developmental delay, macrocephaly, autism, and congenital anomalies (OMIM # 617788). Given the relatively recent discovery of this disorder, it has not been fully characterized. Deep phenotyping of the largest ( n = 43) patient cohort to date identified that hypotonia and congenital heart defects are prominent features that were previously not associated with this syndrome. Both missense variants and putative loss-of-function variants resulted in slow growth in patient-derived cell lines. KMT5B homozygous knockout mice were smaller in size than their wild-type littermates but did not have significantly smaller brains, suggesting relative macrocephaly, also noted as a prominent clinical feature. RNA sequencing of patient lymphoblasts and Kmt5b haploinsufficient mouse brains identified differentially expressed pathways associated with nervous system development and function including axon guidance signaling. Overall, we identified additional pathogenic variants and clinical features in KMT5B -related neurodevelopmental disorder and provide insights into the molecular mechanisms of the disorder using multiple model systems.
The national prevalence of disorders of gut brain interaction in the United Kingdom in comparison to their worldwide prevalence: Results from the Rome foundation global epidemiology study
Jaafari, Hussain, Houghton, Lesley A. , West, Robert , Aziz, Imran , Black, Christopher J. , Corsetti, Maura , Shuweihdi, Farag , Eugenicos, Maria , Paine, Peter , Ford, Alexander C. , Whorwell, Peter J. , Palsson, Olafur S. , Vasant, Dipesh H. , Aziz, Imran , Black, Christopher J , Corsetti, M , Ford, Alexander C , Whorwell, Peter J , Sperber, Ami D , Vasant, Dipesh H , Houghton, L A , Palsson, Olafur S , Agrawal, Anurag, Bangdiwala, Shrikant I.

Mayo Clinic

Neurogastroenterology & Motility | April 5, 2023 | Volume: 35 | Issue: 6 | Pages: No page available

10.1111/nmo.14574 | PMID 37018424 Get It

AbstractBackgroundThere are minimal epidemiological data comparing the burden of disorders of gut brain interaction (DGBI) in the UK with other countries. We compared the prevalence of DGBI in the UK with other countries that participated in the Rome Foundation Global Epidemiology Study (RFGES) online.MethodsParticipants from 26 countries completed the RFGES survey online including the Rome IV diagnostic questionnaire and an in‐depth supplemental questionnaire with questions about dietary habits. UK sociodemographic and prevalence data were compared with the other 25 countries pooled together.Key ResultsThe proportion of participants with at least one DGBI was lower in UK participants compared with in the other 25 countries (37.6% 95% CI 35.5%–39.7% vs. 41.2%; 95% CI 40.8%–41.6%,p = 0.001). The UK prevalence of 14 of 22 Rome IV DGBI, including irritable bowel syndrome (4.3%) and functional dyspepsia (6.8%), was similar to the other countries. Fecal incontinence, opioid‐induced constipation, chronic nausea and vomiting, and cannabinoid hyperemesis (p < 0.05) were more prevalent in the UK. Cyclic vomiting, functional constipation, unspecified functional bowel disorder, and proctalgia fugax (p < 0.05) were more prevalent in the other 25 countries. Diet in the UK population consisted of higher consumption of meat and milk (p < 0.001), and lower consumption of rice, fruit, eggs, tofu, pasta, vegetables/legumes, and fish (p < 0.001).Conclusions and InferencesThe prevalence and burden of DGBI is consistently high in the UK and in the rest of the world. Opioid prescribing, cultural, dietary, and lifestyle factors may contribute to differences in the prevalence of some DGBI between the UK and other countries.
Haploidentical Donor Blood or Marrow Transplantation for Myelodysplastic/Myeloproliferative Overlap Neoplasms: Results from a North American Collaboration
Jain, Tania , Tsai, Hua‐Ling , Elmariah, Hany , Vachhani, Pankit , Wall, Sarah , Gondek, Lukasz P. , Bashey, Asad, Keyzner, Alla , Tamari, Roni , Nadiminti, Kalyan , Ali, Haris , Jones, Richard J. , Gondek, Lukasz , Tamari, Roni , Grunwald, Michael , Gerds, Aaron T , McCurdy, Shannon , Al Malki, Monzr M , Ali, Haris , Gupta, Vikas , Jain, Tania , Elmariah, Hany , Karantanos, Theodoros , Grunwald, Michael R. , Abedin, Sameem , Iqbal, Madiha , Gerds, Aaron T. , Viswabandya, Auro , Malki, Monzr M. Al , Varadhan, Ravi , Gupta, Vikas , Otoukesh, Salman

Mayo Clinic

No container title available | March 21, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2691216/v1 | PMID 36993719 Get It

AbstractHaploidentical donors offer a potentially readily available donor, especially for non-White patients, for blood or marrow transplantation (BMT). In this collaboration across North America, we retrospectively analyzed outcomes of first BMT using haploidentical donor and posttransplantation cyclophosphamide (PTCy) in MDS/MPN-overlap neoplasms (MDS/MPN), an otherwise incurable hematological neoplasm. We included 120 patients, 38% of non-White/Caucasian ethnicity, across 15 centers with median age at BMT 62.5 years. The median follow-up is 2.4 years. Graft failure was reported in 6% patients. At 3-years, nonrelapse mortality (NRM) was 25%, relapse 27%, grade 3-4 acute graft versus host disease (GVHD) 12%, chronic GVHD requiring systemic immunosuppression 14%, progression-free survival (PFS) 48% and overall survival (OS) 56%. On multivariable analysis, statistically significant associations included older age at BMT (per decade increment) with NRM (sdHR 3.28, 95%CI 1.30-8.25), PFS (HR 1.98, 95% 1.13-3.45) and OS (HR 2.01, 95% CI 1.11-3.63), presence of mutation in EZH2/RUNX1/SETBP1 with relapse (sdHR 2.61, 95%CI 1.06-6.44), and splenomegaly at BMT/prior splenectomy with OS (HR 2.20, 95%CI 1.04-4.65). Haploidentical donors are a viable option for BMT in MDS/MPN, especially for those disproportionately represented in the unrelated donor registry. Disease-related factors including splenomegaly and high-risk mutations dominate outcomes following BMT.